Skip to main content
Premium Trial:

Request an Annual Quote

DxS: Apr 18, 2007

DxS announced the launch of its first CE-marked diagnostic kit to detect EGFR gene mutations, the company announced this week.
The TheraScreen: EGFR29 kit will help doctors select lung cancer patients suitable for treatment with tyrosine kinase inhibitor therapies, such as Roche/OSI’s Tarceva and AstraZeneca’s Iressa. 
For some patients, studies show that EGFR mutations correlate with responsiveness to tyrosine kinase inhibitors. The TheraScreen: EGFR29 kit – combining allele-specific and real-time PCR technology – detects 29 of the most common somatic EGFR mutations.
“The TheraScreen kit detects mutations that are frequently missed by other methods, the most common of which is DNA sequencing,” the company said in a statement.

Filed under

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.